Expression And Clinical Significance Of Indoleamine 2,3-dioxygenase IDO And CD25 In Esophageal Carcinoma

AIM:To investigate the expression of IDO (indoleamine 2,3-dioxygenase) and CD25 in esophageal carcinoma, as well as its clinical significance.METHODS:Expressions of IDO, CD25 were detected by immunochemistry technique in 60 cases of human esophageal carcinoma and 12 cases of human tissue adjacent to carcinoma.RESULTS:1. The positive rate of IDO expression in esophageal carcinoma was 78.33%. In tissue adjacent to carcinoma, the positive rate of IDO was 33.33%. The positive rate of IDO expression in cancer cases was higher than that in adjacent to carcinoma cases (P＜0.05).2. The positive rate of CD25 expression in esophageal carcinoma was 91.67%. In tissue adjacent to carcinoma, the positive rate of CD25 was 41.67%. The positive rate of CD25 expression in cancer cases was higher than that in adjacent to carcinoma cases (P＜0.05).3. the over expression of IDO in cancer cases was relative with over expression of CD25, P＜0.01.4. The CD25 expression in carcinoma tissue was not significantly related with age, gender, histological differentiation, infiltration depth, lymph node metastasis and distant metastasis. The IDO expression was significantly related with histological differentiation, infiltration depth, lymph node metastasis.CONCLUSION:The strong expression of IDO (indoleamine 2,3-dioxygenase) may be involved in the progression and lymph node metastasis of esophageal carcinoma.